If you enjoy this content, please share it with a colleague
Mirada Medical Ltd.
RELATED CONTENT
Over the past several years, technological advancements have driven the development of more precise and targeted radiati ...
August 10, 2022 — Mindray North America, a global leader and developer of healthcare technologies and solutions for ...
June 9, 2020 — Mirada Medical, a global leader in artificial intelligence (AI) software for the treatment of cancer, has ...
This is an example of the Mirada DLCExpert deep learning software that automatically identifies organs, segments and ...
February 18, 2019 — Mirada Medical Ltd announced U.S. Food and Drug Administration (FDA) 510(k) clearance for ...
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI) consortium receiving £50M in new funding from the U.K. government. The funding is part of the government’s drive to expedite the development and adoption of AI in healthcare and the National Health System (NHS).
Medical imaging software company Mirada Medical showcased its DLCExpert at the recent American Society for Radiation Oncology (ASTRO) 2018 annual meeting, oct. 21-24 in San Antonio, Texas. The product, which has received U.S. Food and Drug Administration (FDA) 510(k) clearance, is the world’s first artificial intelligence (AI)-powered autocontouring solution. The software is already in use in multiple academic medical centers worldwide.
February 22, 2018 — U.K.-based medical imaging software provider Mirada Medical has released DLCExpert, the first ...
Optellum, a high-tech startup in lung cancer and machine learning, and Mirada Medical recently announced a partnership to accelerate the deployment of deep learning technology to market. This collaboration combines the deep technology and clinical expertise of Optellum with the software platforms and rapid development know-how of Mirada. They have partnered to address what they call a huge and growing problem in lung cancer diagnosis: the management of patients with indeterminate pulmonary nodules.
Mirada Medical showcased its latest XD:PACS (picture archiving and communication system) range of molecular imaging products at the 2016 Radiological Society of North America (RSNA) annual meeting, Nov. 27-Dec. 1 in Chicago.